Toll-like receptor 7 deficiency protects apolipoprotein E-deficient mice from diet-induced atherosclerosis

Cong-Lin Liu1,2, Marcela M. Santos2, Cleverson Fernandes2, Mengyang Liao2, Karine Iamarene2, Jin-Ying Zhang1, Galina K. Sukhova2 & Guo-Ping Shi1,2

Toll-like receptor 7 (TLR7) mediates autoantigen and viral RNA-induced cytokine production. Increased TLR7 expression in human atherosclerotic lesions suggests its involvement in atherogenesis. Here we demonstrated TLR7 expression in macrophages, smooth muscle cells (SMCs), and endothelial cells from mouse atherosclerotic lesions. To test a direct participation of TLR7 in atherosclerosis, we crossbred TLR7-deficient (Tlr7−/−) mice with apolipoprotein E-deficient (Apoe−/−) mice and produced Apoe−/−Tlr7−/− and Apoe−/−Tlr7+/+ littermates, followed by feeding them an atherogenic diet to produce atherosclerosis. Compared to Apoe−/−Tlr7+/+ mice, Apoe−/−Tlr7−/− mice showed reduced aortic arch and sinus lesion areas. Reduced atherosclerosis in Apoe−/−Tlr7−/− mice did not affect lesion macrophage-positive area and CD4+ T-cell number per lesion area, but reduced lesion expression of inflammatory markers major histocompatibility class II and IL6, lesion matrix-degrading proteases cathepsin S and matrix metalloproteinase-9, and systemic serum amyloid A levels. TLR7 deficiency also reduced aortic arch SMC loss and lesion intima and media cell apoptosis. However, TLR7 deficiency did not affect aortic wall elastin fragmentation and collagen contents, or plasma lipoproteins. Therefore, TLR7 contributes to atherogenesis in Apoe−/− mice by regulating lesion and systemic inflammation. A TLR7 antagonist may mitigate atherosclerosis.

Toll-like receptors (TLRs) are pattern recognition receptors that recognize distinct evolutionarily conserved structures on pathogens, termed pathogen-associated molecular patterns (PAMPs) and play essential roles in innate immunity1, 2. Recent studies suggest an involvement of TLRs in atherosclerosis3–5. However, the role of TLRs in atherosclerosis has been controversial. TLR3 and TLR4 activation promoted atherosclerosis6. Deficiency of TLR2, TLR3, and TLR4 protected low-density lipoprotein receptor-deficient (Ldlr−/−) mice6–9 and apolipoprotein E-deficient (Apoe−/−) mice10 from atherosclerosis. However, these TLRs have also been suggested to play protective roles in murine atherosclerosis. TLR4 signaling protected Apoe−/− mice from periodontal pathogen-induced atherosclerosis11. In Apoe−/− mice, TLR3 deficiency accelerated the onset of atherosclerosis12. Absence of TLR9 also protected Apoe−/− mice from spontaneous atherosclerosis13.

While TLR2 and TLR4 are localized on cell surface, TLR3, TLR7, and TLR9 are localized to the endosomal membrane where these TLRs mediate autoantigen and bacterial and viral nucleic acid infection-induced inflammatory cytokine production. For example, viral single-strand RNA (ssRNA) binding on TLR714 is required for B cell proliferation, and such activity of TLR7 is specific for RNA-containing antigens15. TLR stimulation by microbial infection results in elevated production of IL6 and other cytokines that block regulatory T-cell de novo generation16 and function17, which play protective roles in atherosclerosis18, 19. The role of TLR7 in atherosclerosis has also been controversial. In normal human arteries, including aorta, carotid, iliac, mesenteric, subclavian, and temporal, there was negligible expression of TLR720. However, human atherosclerotic lesions contained elevated levels of TLR721, suggesting an involvement of TLR7 in atherosclerosis. TLR7 signaling is mediated by MyD88, which activates downstream interferon regulatory factor 5 (IRF5) and IRF7 for the production of inflammatory cytokines. Toll-like receptor 7 (TLR7) mediates autoantigen and viral RNA-induced cytokine production. Increased TLR7 expression in human atherosclerotic lesions suggests its involvement in atherogenesis. Here we demonstrated TLR7 expression in macrophages, smooth muscle cells (SMCs), and endothelial cells from mouse atherosclerotic lesions. To test a direct participation of TLR7 in atherosclerosis, we crossbred TLR7-deficient (Tlr7−/−) mice with apolipoprotein E-deficient (Apoe−/−) mice and produced Apoe−/−Tlr7−/− and Apoe−/−Tlr7+/+ littermates, followed by feeding them an atherogenic diet to produce atherosclerosis. Compared to Apoe−/− Tlr7+/+ mice, Apoe−/− Tlr7−/− mice showed reduced aortic arch and sinus lesion areas. Reduced atherosclerosis in Apoe−/− Tlr7−/− mice did not affect lesion macrophage-positive area and CD4+ T-cell number per lesion area, but reduced lesion expression of inflammatory markers major histocompatibility class II and IL6, lesion matrix-degrading proteases cathepsin S and matrix metalloproteinase-9, and systemic serum amyloid A levels. TLR7 deficiency also reduced aortic arch SMC loss and lesion intima and media cell apoptosis. However, TLR7 deficiency did not affect aortic wall elastin fragmentation and collagen contents, or plasma lipoproteins. Therefore, TLR7 contributes to atherogenesis in Apoe−/− mice by regulating lesion and systemic inflammation. A TLR7 antagonist may mitigate atherosclerosis.

Toll-like receptors (TLRs) are pattern recognition receptors that recognize distinct evolutionarily conserved structures on pathogens, termed pathogen-associated molecular patterns (PAMPs) and play essential roles in innate immunity1, 2. Recent studies suggest an involvement of TLRs in atherosclerosis3–5. However, the role of TLRs in atherosclerosis has been controversial. TLR3 and TLR4 activation promoted atherosclerosis6. Deficiency of TLR2, TLR3, and TLR4 protected low-density lipoprotein receptor-deficient (Ldlr−/−) mice6–9 and apolipoprotein E-deficient (Apoe−/−) mice10 from atherosclerosis. However, these TLRs have also been suggested to play protective roles in murine atherosclerosis. TLR4 signaling protected Apoe−/− mice from periodontal pathogen-induced atherosclerosis11. In Apoe−/− mice, TLR3 deficiency accelerated the onset of atherosclerosis12. Absence of TLR9 also protected Apoe−/− mice from spontaneous atherosclerosis13.

While TLR2 and TLR4 are localized on cell surface, TLR3, TLR7, and TLR9 are localized to the endosomal membrane where these TLRs mediate autoantigen and bacterial and viral nucleic acid infection-induced inflammatory cytokine production. For example, viral single-strand RNA (ssRNA) binding on TLR714 is required for B cell proliferation, and such activity of TLR7 is specific for RNA-containing antigens15. TLR stimulation by microbial infection results in elevated production of IL6 and other cytokines that block regulatory T-cell de novo generation16 and function17, which play protective roles in atherosclerosis18, 19. The role of TLR7 in atherosclerosis has also been controversial. In normal human arteries, including aorta, carotid, iliac, mesenteric, subclavian, and temporal, there was negligible expression of TLR720. However, human atherosclerotic lesions contained elevated levels of TLR721, suggesting an involvement of TLR7 in atherosclerosis. TLR7 signaling is mediated by MyD88, which activates downstream interferon regulatory factor 5 (IRF5) and IRF7 for the production of inflammatory cytokines.
cytokines (e.g. IL6 and TNF-α) and type 1 interferon (e.g. IFN-α), respectively33. In a femoral artery cuff placement-induced neointima thickness model in hypercholesterolemic ApoE−/−Leiden mice, TLR7 expression was increased 14 days after the surgery. Blocking of TLR7 signaling with its antagonist reduced neointimal formation, luminal stenosis, and foam cell formation by greater than 60% with concurrent reduction of arterial wall macrophage infiltration. Stimulation of macrophages with the TLR7 ligand imiquimod enhanced TNF-α expression33. Similar observations were obtained in collar placement-induced carotid artery atherosclerosis-like lesion development in hypercholesterolemic rabbits. TLR7 activation with imiquimod increased carotid artery lesion intima area, lipid deposition, and lesion macrophage and lymphocyte contents34. However, primary cultured human aortic wall endothelial cells (ECs) and smooth muscle cells (SMCs) produced chemokines IL8 and E-selectin in responding to ligands of TLR3 (Poly I:C), TLR4 (lipopolysaccharide), and TLR5 (flagellin), but do not respond to TLR7 ligand ssRNA32. In ApoE−/− mice fed a chow diet, TLR7 deficiency increased aortic root atherosclerotic lesion area and lesion macrophage accumulation, with reduced lesion SMC and collagen contents. In the peripheral blood, TLR7 deficiency led to increased plasma monocyte chemotactant protein-1 (MCP-1) and increased inducible nitric oxide synthase (iNOS)-positive M1 macrophage contents. Macrophages from these mice also produced more MCP-1, TNF-α, IL6, and IL10 after stimulation with a TLR2 ligand lipoteichoic acid31. In lupus-prone Faslgld/gld ApoE−/− mice, deficiency of IRF5 increased aortic root and arch lesion area and plasma levels of triglyceride, cholesterol, phospholipids, and non-esterified fatty acids, with concurrent reduction of plasma IL10 levels. Bone marrow macrophages from IRF5-deficient mice also showed reduced IL10 production in response to TLR7 ligands R848 or R837. Therefore, the exact role of TLR7 in atherosclerosis remains uncertain and may depend on different experimental model systems.

In this study, we used TLR7-deficient (Tlr7−/−) mice and atherogenic diet-fed ApoE−/− mice to test whether TLR7 deficiency affects atherogenesis differently from ApoE−/− mice not on an atherogenic diet or mice on a Fasbgld/gld lupus background.

Materials and Methods

Mice and experimental model. Both ApoE−/− mice (C57BL/6, N = 15, #002052) and Tlr7−/− mice (C57BL/6, N > 10, #008380) were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and crossed to generate ApoE−/− Tlr7−/− mice and ApoE−/− Tlr7+/+ littermates. Eight to ten-week-old male mice were used to induce atherosclerosis by feeding a high cholesterol diet (1.25%) (D12108c, Research Diets Inc. New Brunswick, NJ). After 3 months on this diet, mice from both groups were sacrificed with carbon dioxide narcosis, followed by cardiac puncture blood collection, heart and aortic arch tissue harvest. Aortic root was prepared by cutting away about 70% of the ventricles, and embedding the upper portion of the heart that contained the aortic root in optimum cutting temperature OCT for sectioning as described previously27. Six μm aortic root sections were prepared for oil-red O (ORO) staining to determine atherosclerotic lesion sizes. To analyze atherosclerotic lesion in the aortic arch, we used longitudinal sections from the whole arch embedded in OCT. We collected only sections that contained all three branches (brachiocephalic artery, left common carotid artery, and left subclavian artery) as we reported27. Aortic arch sections were also stained with ORO to determine atherosclerotic lesion sizes. We can typically cut 8–10 serial numbered slides (3 sections per slide) and select for each staining the slides with the same lesion location, which corresponds to the same serial slide number. For example, we used one serial numbered slide for Mac-3, CD4, and major histo compatibility complex class II (MHC-II) for all mice, and used another same serial numbered slides from all mice for ORO staining. This approach gives central location of each lesion in each aortic arch with the maximal comparability of quantitative data. All animal procedures conformed to the Guideline for the Care and Use of Laboratory Animals published by the US National Institutes of Health and were approved by the Harvard Medical School Standing Committee on Animals (protocol # 03759).

Immunohistological analysis. Serial aortic arch cryostat cross-sections were used for immunostaining to detect TLR7 (1:150, #ab45371, Abcam, Cambridge, MA), macrophages (Mac-3, 1:900, #553322, BD Biosciences, San Jose, CA), CD4+ T cells (CD4, 1:90, #553043, BD Biosciences), MHC-II (1:250, #556999, BD Biosciences), elastin (Modified Verhoeff Van Gieson Elastic Stain Kit, HT25A-IKT, Sigma-Aldrich, St. Louis, MO), collagen (0.1% Sirius Red; #09400, Polysciences Inc., Warrington, PA), SMC (#sc-146, Santa Cruz Biotechnologies, Inc, Dallas, TX), TLR2 (1:50, #ab1655, Abcam, Cambridge, MA), cathepsin B (CatS) (1:750, #F3777, Sigma-Aldrich), IL6 along with rabbit IgG isotype (IL6, 1:50, #ab6672, Abcam), IL4 (IL4, 1:50, #ab11254, Abcam), TGF-β (1:300, #sc-146, Santa Cruz Biotechnologies, Inc, Dallas, TX), TLR2 (1:50, #ab1655, Abcam, Cambridge, MA), cathepsin S (CatS) (1:100)35, and matrix metalloproteinase-9 (MMP-9) (1:400, #AB804, Chemicon International, Temecula, CA). Apoptotic cells in lesions were determined with the in situ apoptosis detection kit according to the manufacturer’s instructions (#S7100, Millipore, Billerica, MA). Immunostained slides were visualized with either the liquid diamobenzindazol (DAB) substrate chromogen system (#K3468, DAKO, Carpinteria, CA) and counter-stained with methyl green (#H-3402, Vector Laboratories, Inc, Burlingame, CA) (TGF-β, IL-4, IL-6, and TLR7), or with 3-amino-9-ethyl carbazole (#K3464, AEC) (DAKO) and counter-stained with Gill’s hematoxylin solution (GHS316, Sigma-Aldrich) (macrophage, MHC-II, CD4+ T cell and SMC). Elastin degradation, collagen content, and media SMC accumulation were graded according to the grading keys that were previously described30,31. CD4+ T cells and TUNEL-positive apoptotic cells were counted manually in a blinded fashion and presented as numbers per aortic section. Images of the relative macrophage, MHC-II, IL6, and TGF-β contents within the aortas were captured by a microscope VS1200 Whole Slide Scanner (Olympus) and quantified by measuring the immunostaining signal-positive areas using computer-assisted image analysis software (Image-Pro Plus; Media Cybernetics, Bethesda, MD). Mouse experiments were performed, and data were analyzed in a blinded fashion by at least two observers.

Immunofluorescent double staining. Cell type (macrophage, SMC, and EC)-specific expression of TLR7 in mouse atherosclerotic lesions was determined by immunofluorescent double staining using rabbit anti-mouse...
TLR7 monoclonal antibody (1:100, ab45371, Abcam) together with rat anti-mouse Mac-2 monoclonal antibody (macrophages, 1:100, CL8942AP, CEDARLANE, Burlington, NC), purified rat anti-mouse CD31 monoclonal antibody (EC, 1:900, #553370, BD Biosciences), and FITC-conjugated mouse anti-α-smooth muscle actin monoclonal antibody (SMC, 1:500, F3777, Sigma-Aldrich). Mouse aortic arch lesion macrophage and SMC apoptosis was also detected by immunofluorescent double staining with Alexa Fluor® 594-conjugate cleaved caspase-3 (Asp175) (D3E9) rabbit monoclonal antibody (1:200, #8172, Cell Signaling Technology, Danvers, MA) together with rat anti-mouse Mac-2 monoclonal antibody or FITC-conjugated mouse anti-α-smooth muscle actin monoclonal antibody as mentioned above. Images were collected under an Olympus FluoView™ FV1000 Confocal Microscope.

Plasma protein measurements. Mouse plasma was collected after mice were fasted overnight and stored at −80 °C until analysis. Plasma IL6 (#88-7064-88), IFN-γ (#88-7314-88) (eBioscience, Inc., San Diego, CA), and serum amyloid A (SAA) (#MSAA00, R&D Systems, Minneapolis, MN) levels were determined using ELISA kits according to the manufacturers’ instructions. Plasma total cholesterol, triglyceride, and high-density lipoprotein (HDL) levels were determined using reagents from Pointe Scientific (Canton, MI) and the level of low-density lipoproteins (LDL) was calculated as the following formula: LDL = total cholesterol − HDL − (triglycerides/5) as previously reported32. Investigators were blinded to the sources of samples during the assays.

Statistical analysis. All mouse data were expressed as mean ± SEM. Due to our small sample sizes and often skewed data distributions, we performed a pairwise non-parametric Mann-Whitney test followed by Bonferroni corrections to examine the statistical significances. SPSS 16.0 was used for analysis.

Results

TLR7 expression in mouse atherosclerotic lesions. Prior studies revealed elevated TLR7 expression in human atherosclerotic lesions21, but negligible TLR7 in normal human arteries30. We obtained similar observations in mouse atherosclerotic lesions. TLR7 immunostaining did not detect TLR7 expression in normal mouse aorta (Fig. 1A). In contrast, rabbit anti-mouse TLR7 antibody revealed elevated TLR7 expression in the intima

Figure 1. TLR7 expression in mouse atherosclerotic lesions. (A) Rabbit-anti-mouse TLR7 monoclonal antibody immunostaining of a normal mouse aortic arch. Scale: 1 mm, inset scale: 200 μm. (B) Rabbit-anti-mouse TLR7 monoclonal antibody immunostaining of an aortic arch from an Apoe−/− mouse with atherosclerosis showed TLR7 expression in intima and adventitia. Scale: 1 mm, inset scales: 200 and 68 μm. Arrows indicate TLR7-positive cells. (C) Rabbit IgG isotype immunostaining of a parallel aortic arch from an Apoe−/− mouse with atherosclerosis. Scale: 1 mm, inset scale: 200 μm. (D–F) Immunofluorescent double staining of mouse aortic arch atherosclerotic lesions with antibodies against TLR7 and cell type markers (Mac-2, α-actin, and CD31) for macrophage, SMC, and EC from both the lumen and adventitia microvessels. Scale: 100 μm, inset scale: 25 μm. Arrows in the insets indicate TLR7-positive macrophages (D), SMCs (E), and ECs in lumen and adventitia (F).
and adventitia in aortic arches from Apoe−/− mice that had consumed an atherogenic diet for 3 months (Fig. 1B).

Immunostaining of a parallel section using a rabbit IgG isotype, as negative control, revealed negligible signal (Fig. 1C).

Immunofluorescent double staining of mouse aortic arch atherosclerotic lesions from Apoe−/− mice demonstrated TLR7 expression in macrophages (Fig. 1D, left two panels), SMCs (Fig. 1E, middle two panels), and ECs (Fig. 1F, right three panels).

TLR7 deficiency reduced atherosclerotic lesion size and lesion inflammation. To test a direct role of TLR7 in atherosclerosis, we generated Apoe−/− Tlr7+/+ and Apoe−/− Tlr7−/− littermate control mice. To induce atherosclerosis, we fed 8 to 10 weeks old male mice an atherogenic diet for 3 months. Mouse bodyweights or blood pressures did not differ between the two types of mice before or after the atherogenic diet. We assessed atherosclerotic lesion sizes in both the aortic arch and aortic root by staining frozen sections with ORO. In aortic arches, ORO staining revealed significantly smaller atherosclerotic lesions and lipid deposition areas from Apoe−/− Tlr7+/+ mice than those from Apoe−/− Tlr7−/− control mice (Fig. 2A). We obtained similar conclusion when mouse aortic roots were analyzed. ORO staining also demonstrated significantly smaller atherosclerotic lesions and lipid deposition areas in aortic roots from Apoe−/− Tlr7+/+ mice than those from Apoe−/− Tlr7−/− control mice (Fig. 2B).

We measured lesion contents of macrophages, CD4+ T cells, and MHC-II levels as indication of inflammatory cell infiltration and inflammation according to previously described methods28. Compared with the Apoe−/− Tlr7+/+ control mice, aortic arches from Apoe−/− Tlr7−/− mice had significantly smaller Mac-3-positive macrophage areas (Fig. 3A), fewer lesion CD4+ T cells (Fig. 3B), and smaller MHC-II-positive areas (Fig. 3C). Significant smaller aortic arch atherosclerotic lesion sizes in Apoe−/− Tlr7−/− mice than those in Apoe−/− Tlr7+/+ control mice may account for reduced lesion contents of macrophages, CD4+ T cells, and MHC-II-positive areas from Apoe−/− Tlr7−/− mice. When Mac-3-positive macrophage areas were expressed as percentage of total lesion areas, the macrophage contents in Apoe−/− Tlr7+/+ control mice remained higher than those in Apoe−/− Tlr7−/− mice, but such a difference did not reach statistical significance (26.27 ± 11.34% vs. 10.50 ± 2.51%, P = 0.141) (Fig. 3D). Similarly, when CD4+ T-cell numbers were expressed as those of each mm², we found comparable lesion CD4+ T-cell contents between Apoe−/− Tlr7+/+ control mice and Apoe−/− Tlr7−/− mice (14.90 ± 3.45 number/mm² vs. 18.10 ± 3.30 number/mm², P = 0.341) (Fig. 3E). However, when MHC-II-positive areas were expressed as percentage of total lesion areas, we still saw significantly higher lesion MHC-II contents in Apoe−/− Tlr7+/+ control mice than in Apoe−/− Tlr7−/− mice (42.13 ± 10.11% vs. 5.67 ± 1.03%, P = 0.002) (Fig. 3F).

IL6 is an important TLR7 downstream inflammatory product. TLR7 activation increases IL6 production33, 34. IFN-γ is another common pro-inflammatory cytokine in atherosclerosis. TLR7 activation can also indirectly
produce IFN-γ\(^35, 36\). In contrast, TLR7 activation decreases TGF-β expression\(^37\). In turn, TGF-β inhibits TLR7 downstream pro-inflammatory molecule expression\(^38, 39\). IL4 is an anti-inflammatory cytokine that regulates TLR7 responses to viral infections\(^40\) or B-cell activation\(^41\). Therefore, TLR7 deficiency may attenuate atherosclerosis (Fig. 2A and B) by altering the production of these pro- and anti-inflammatory cytokines. Mouse plasma IFN-γ levels were undetectable by ELISA. Plasma IL6 levels from Apoe\(^−/−\) Tlr7\(^−/−\) mice were lower than those from the Apoe\(^−/−\) Tlr7\(^+/+\) littermates, but such a difference did not reach statistical significance (Fig. 4A). In the aortic arches, however, lesion IL6-positive areas were significantly lower in Apoe\(^−/−\) Tlr7\(^−/−\) mice than those in Apoe\(^−/−\) Tlr7\(^+/+\) mice (Fig. 4B, left and middle panels). Rabbit anti-mouse IL6 antibody specificity in mouse aortic arch immunostaining was verified using rabbit IgG isotype to stain the parallel sections and showed no immunoreactive signals (Fig. 4B, right panels). Lesion anti-inflammatory cytokines IL4- and TGF-β-positive areas were slightly elevated in aortic arches from the Apoe\(^−/−\) Tlr7\(^−/−\) mice, but such changes were also not statistically significant, compared with those from the Apoe\(^−/−\) Tlr7\(^+/+\) littermate control mice (Fig. 4C,D). Consistent with the hypothesis that TLR7 deficiency reduces lesion or systemic inflammation, plasma inflammation marker SAA was found significantly lower in Apoe\(^−/−\) Tlr7\(^−/−\) mice than in Apoe\(^−/−\) Tlr7\(^+/+\) control mice (Fig. 4E).

Figure 3. TLR7 deficiency and aortic arch atherosclerotic lesion inflammatory cell accumulation in male Apoe\(^−/−\) mice. (A) Mac-3-positive area in pixel. (B) Lesion CD4\(^+\) T-cell number. (C) Lesion MHC class-II-positive area in pixel. (D) Mac-3-positive area versus total lesion area in percentage. Representative images are shown to the right. Scale: 200 μm, inset scale: 100 μm. (E) Lesion CD4\(^+\) T-cell number per mm\(^2\). Representative images are shown to the right. Scale: 100 μm. (F) Lesion MHC class-II-positive area versus total lesion area in percentage. Representative images are shown to the right. Scale: 100 μm. Numbers and genotypes of mice are indicated in the legends.
Both endolysosomal TLRs (e.g. TLR7, and TLR9) and cell surface TLRs (e.g. TLR2 and TLR4) share the same MyD88 and IRAK4/TRAF6 signaling pathways that lead to the production of pro-inflammatory cytokines. TLR7 deficiency is expected to reduce the production of lesion pro-inflammatory IL6 (Fig. 4B). Yet, it is also possible that endolysosomal TLR7 deficiency may affect the expression of cell surface TLRs. Therefore, reduced lesion IL6 (Fig. 4B) may come not only from TLR7 deficiency but also impaired expression of cell surface TLRs. We tested this possibility by immunostaining aortic arch atherosclerotic lesion TLR2 expression and did not detect significant differences in TLR2 expression in lesions between the Apoe−/− Tlr7−/− and Apoe−/− Tlr7+/+ control mice (Fig. 4F). Instead, we found that atherosclerotic lesions from Apoe−/− Tlr7−/− mice contained significantly lower levels of both CatS (Fig. 4G) and MMP-9 (Fig. 4H), two common proteases that have been reported from atherosclerotic lesions, up-regulated by inflammatory cytokines, and play detrimental roles in atherogenesis.

TLR7 deficiency reduced lesion SMC loss and cell death. SMCs are the main cell type in the arterial wall and maintain the tissue phenotype and functional plasticity. These cells may switch their contractile phenotype into pro-inflammatory phenotype during atherogenesis-mediated inflammation, thereby undergoing apoptosis and cell loss. SMC loss is associated with plaque rupture and lesion outward remodeling, and potential aneurysm formation. Indeed, plaques from patients with atherosclerosis with unstable symptoms showed higher levels of apoptosis than those with stable lesions. In aortic arches from Apoe−/− Tlr7−/− mice, we found significantly lower grade of SMC loss than that from Apoe−/− Tlr7+/+ control mice (Fig. 5A). As expected, we detected significantly fewer TUNEL-positive apoptotic cells in the aortic arch media (Fig. 5B) and intima (Fig. 5C) from Apoe−/− Tlr7−/− mice than those from Apoe−/− Tlr7+/+ mice. To determine the cell types that underwent apoptosis in atherosclerotic lesions from these mice, we performed immunofluorescent double staining using anti-mouse cleaved caspase-3 and antibodies against SMC α-smooth muscle actin and macrophage Mac-2. Cleaved caspase-3 and α-actin double positive apoptotic SMCs were detected in both the intima (Fig. 5D) and media (Fig. 5E) from Apoe−/− Tlr7+/+ and Apoe−/− Tlr7−/− mice. We also detected cleaved caspase-3 and Mac-2 double positive apoptotic macrophages in atherosclerotic lesions from both Apoe−/− Tlr7+/+ and Apoe−/− Tlr7−/− mice (Fig. 5F).
Figure 5. TLR7 deficiency reduces aortic arch atherosclerotic lesion SMC loss and cell apoptosis in male Apoe<sup>−/−</sup> mice. (A) Media SMC loss grade. Scale: 200 µm. (B) Media TUNEL-positive apoptotic cell number per section. Scale: 100 µm. (C) Intima TUNEL-positive apoptotic cell number per section. Scale: 100 µm. Media with clear elastic fibers and intima are framed. Representative images are shown to the middle panels. (D) Immunofluorescent double staining detected cleaved caspase-3 (Casp)-positive apoptotic SMC in the intima. Scale: 200 µm. Inset scale: 100 µm. (E) Cleaved caspase-3 (Casp)-positive apoptotic SMC in the media. Scale: 100 µm. (F) Cleaved caspase-3 (Casp)-positive apoptotic macrophages (Mac) in the lesions. Scale: 200 µm. Inset scale: 100 µm. Arrows indicate apoptotic cells. Numbers and genotypes of mice are indicated in the legends.

TLR7 deficiency did not affect arterial wall matrix protein expression or plasma lipoproteins. Besides apoptosis, media SMC loss may also be associated with elastin degradation<sup>49</sup>. Collagen is also a major component of the fibrotic cap that maintains the cap strength and integrity<sup>51</sup>. While CatS is a potent elastase<sup>52</sup>, MMP-9 has both elastolytic and collagenolytic activities<sup>53–55</sup>. Reduced expression of lesion CatS and MMP-9 in Apoe<sup>−/−</sup> Tlr7<sup>−/−</sup> mice may reduce lesion elastin fragmentation and increase collagen deposition. Yet, both elastin fragmentation and collagen contents in the aortic arches from both Apoe<sup>−/−</sup> Tlr7<sup>−/−</sup> and Apoe<sup>−/−</sup> Tlr7<sup>+/+</sup> mice did not differ (Fig. 6A,B), suggesting that the reduced media SMC loss in Apoe<sup>−/−</sup> Tlr7<sup>−/−</sup> mice was not due to changes in arterial wall elastin and collagen contents, although expression of both CatS and MMP-9 was reduced in lesions from these mice. Reduced lesion expression of these proteases in Apoe<sup>−/−</sup> Tlr7<sup>−/−</sup> mice may contribute to reduced lesion cell apoptosis as both are known to promote cell apoptosis<sup>56, 57</sup>. Elevated plasma total cholesterol, LDL, triglyceride levels, and reduced plasma HDL are associated with the development of atherosclerosis in humans and mice<sup>58, 59</sup>. After consuming an atherogenic diet for 3 months, both Apoe<sup>−/−</sup> Tlr7<sup>−/−</sup> and Apoe<sup>−/−</sup> Tlr7<sup>+/+</sup> mice had comparable levels of plasma total cholesterol, LDL, triglyceride, and HDL (Fig. 6C–F).

Discussion

TLR7 is an endolysosome membrane receptor that mediates endogenous antigen or viral/bacterial ssRNA-induced inflammation<sup>14, 15, 40</sup>. This study demonstrated a detrimental role of TLR7 in diet-induced atherosclerosis in Apoe<sup>−/−</sup> mice by increasing lesion inflammation (MHC-II), lesion pro-inflammatory cytokine expression (IL6), lesion protease expression (CatS, and MMP-9), and systemic inflammation (plasma SAA). However, our observations are controversial to what were reported in Apoe<sup>−/−</sup> mice that consumed a chow diet<sup>21</sup>, although this current study agrees with the observations that TLR7 antagonist blocked macrophage activation, foam cell formation, and neointima development in a femoral artery cuff placement-induced neointima thickening in Apoe<sup>−/−</sup>X3-Leiden mice<sup>23</sup>. Our study also agrees with the conclusion from the hypercholesterolemic rabbits, in which TLR7 activation with imiquimod increased collar placement-induced carotid artery atherosclerotic lesions<sup>14, 15, 60</sup>. This study demonstrated a detrimental role of TLR7 in diet-induced atherosclerosis in Apoe<sup>−/−</sup> mice by increasing lesion inflammation (MHC-II), lesion pro-inflammatory cytokine expression (IL6), lesion protease expression (CatS, and MMP-9), and systemic inflammation (plasma SAA).

In male Apoe<sup>−/−</sup> mice, decreased atherosclerosis from the study by Salagianni et al.<sup>21</sup>, atherosclerotic lesion in the aortic root was enlarged in the absence of TLR7, along with elevated lesion lipid and macrophage contents, compared with the Apoe<sup>−/−</sup> control mice. In our study, after feeding the same male Apoe<sup>−/−</sup> Tlr7<sup>−/−</sup> mice an atherogenic diet, we detected reduced atherosclerosis and lipid deposition in both aortic arch and root from these mice, compared with the Apoe<sup>−/−</sup> Tlr7<sup>+/+</sup> littermates. It is possible that such discrepancies between the two studies were because of the differences in diet components. Dietary and commensal sources of PAMPs may activate TLR7 differently between chow and high cholesterol diets<sup>61</sup>. Indeed, similar atherosclerosis phenotype
changes because of diet differences (chow diet versus atherogenic diet) have been reported previously in the same male IL18-deficient Apoe−/− (Apoε−/− Il18−/−) mice. When mice were fed a chow diet and analyzed at 24 weeks of age, spontaneous atherosclerotic lesions were significantly reduced in Apoe−/− Il18−/− mice, compared with those in Apoe−/− control mice. In contrast, when the same mice were fed a high cholesterol atherogenic diet at 5 weeks of age for 12 weeks, Apoe−/− Il18−/− mice developed significantly larger atherosclerotic lesions than did the Apoe−/− mice. It was hypothesized that atherogenic diet may alter local and systemic inflammation. The role of endolysosomal TLRs in atherosclerosis has been controversial among all tested members. In atherogenic diet-fed Ldlr−/− and Apoe−/− mice, genetic depletion of TLR3 protected the mouse aortic wall from medial degradation with increased lesion collagen deposition and medial SMC content, although TLR3 deficiency did not affect lesion areas. In contrast, when Apoe−/− mice were fed a chow diet for 15 weeks, TLR3 deficiency increased aortic lesion atherosclerotic lesion area. A major difference between the two studies is the diet. However, diet alone may not explain the discrepancies between these studies. In Apoe−/− mice on a chow diet, TLR9 antagonist reduced aortic root atherosclerosis with decreased lesion inflammatory cell accumulation and increased lesion collagen and SMCs. In ApoE*3 Leiden mice being fed a chow diet, TLR9 antagonist also reduced femoral artery cuff placement-induced neointima thickening and foam cell formation. When Apoe−/− mice were on an atherogenic diet for 7 weeks, TLR9 activation with a high dose of its agonist Cpg oligodeoxynucleotide (ODN) enhanced atherosclerosis in the aortic root. All these observations, regardless of diet types, point to a detrimental role of TLR9 in atherosclerosis. However, in an independent study of Apoe−/− mice on an atherogenic diet for 8 weeks, TLR9 deficiency (Apoe−/− Tlr9−/−) increased aortic root atherosclerosis and lesion CD4+ T-cell content.

Figure 6. TLR7 deficiency does not affect aortic arch lesion matrix proteins or plasma lipid profile. (A) Lesion elastin fragmentation grade. (B) Lesion Sirius red-positive collagen grade. (C–F) Plasma total cholesterol, LDL, triglyceride, and HDL levels. Numbers and genotypes of mice are indicated in the legends.
CD4+ T-cell depletion in these mice reduced atherosclerosis, suggesting a role of TLR9 in regulating CD4+ T cells in atherosclerosis. In the same study, TLR9 activation with its agonist CpG ODN1668 decreased aortic root atherosclerosis13. These observations suggest a protective role of TLR9 in atherosclerosis. Obviously, the use of different diets may not explain all the discrepancies in the role of TLR9 in atherosclerosis and additional mechanisms may be involved and merit further investigation. A high cholesterol atherogenic diet is commonly used to produce atherosclerosis in atherosclerosis-prone Apoe−/− mice or in Ldlr−/− mice66–69. Such diet may lead to steatosis and systemic inflammation, as part of its mechanism in atherosclerosis, abdominal aortic aneurysm, obesity, and diabetes studies66–72. Reduced atherosclerotic lesion IL6 expression and plasma SAA levels in Apoe−/− Tlr7−/− mice compared with those from Apoe−/− control mice from our study supported a role of TLR7 in regulating local and systemic inflammation. An atherogenic diet may affect TLR7 activation cascade, thereby changing downstream inflammatory molecule expression and atherosogenesis. This hypothesis is consistent to several prior studies. For example, in C57BL/6 wild-type mice, TLR7 activation with R848 induced the production of IL10, IL6, TNF-α, and IL12 in a dose- and time-dependent manner21. In mouse macrophages, TLR7 activation with imiquimod induced macrophage production of IL6, MCP-1, RANTES (regulated on activation, normal T cell expressed and secreted), and TNF-α24. Effector T cells from imiquimod-treated squamous cell carcinomas produced more IFN-γ, granzyme, and perforin, and less IL-10 and TGF-β than T cells from untreated tumors31. All these data indicate a pro-inflammatory role of TLR7 in macrophages and lymphocytes. However, we cannot explain why macrophages from Tlr7−/− mice responded to TLR2 ligand lipoteichoic acid and produced significantly more MCP-1, IL6, and IL10 than those from wild-type control mice in a study from Salagiani et al.22.

Different from endolysosomal TLRs, cell surface TLRs such as TLR2 and TLR4 have been proven detrimental in atherosclerosis from most tested experimental models. In Apoe−/− mice on an atherogenic diet or a chow diet, deficiency of TLR4 or its signaling molecule MyD88 reduced aortic atherosclerosis, lesion lipid and macrophage contents, and peripheral IL1α, IL2 and MCP-1 levels25, 76. Similar observations were made in Ldlr−/− mice. Deficiency of TLR4 reduced atherosclerosis and plasma cholesterol and triglyceride, although did not affect obesity, hyperinsulinemia, or glucose intolerance after mice were fed a diabetogenic diet8. Similarly, TLR2-deficient Apoe−/− mice on a chow diet or an atherogenic diet or Apoe−/− mice on a chow diet but treated with an anti-mouse TLR2 antibody all demonstrated reduced atherosclerotic lesion size, lipid accumulation, macrophage and MCP-1 contents, and expression of cytokines (TNF-α and IL6) and associated transcription factors (NF-κB and STAT3)75, 76. It is possible that dietary and commensal sources of PAMPs from mice fed a chow and a high cholesterol diets may activate endolysosomal TLRs differently from cell surface TLR, a hypothesis that was not tested in this study.

The exact ligands that activate TLR7 during atherogenesis remain unknown. This is an interesting and important topic for further exploration. Endogenous TLR7 ligands include mainly ssRNA such as those from viral infections79–81, or even single nucleotide such as guanosine (G)2′-deoxyguanosine (dG)82. Such nucleotide(s) in atherosclerotic lesions may activate TLR7 and promote atherosclerosis. For example, hepatitis C virus RNA and active cytomegalovirus were found in human atherosclerotic lesions82, 83. Hepatitis C infection facilitates human atherosclerosis84 and herpesvirus infection accelerates atherosclerosis in the Apoe−/− mice85. It is possible that these virus affects atherosclerosis by activating TLR7. Nevertheless, results from this study support a pro-inflammatory role of TLR7 in atherogenic diet-induced atherosclerosis in Apoe−/− mice. It is possible that TLR7 antagonists may have therapeutic potential in atherosclerosis and possibly other cardiovascular diseases86.

References
1. Akira, S., Uematsu, S. & Takeuchi, O. Pattern recognition and innate immunity. Cell 124, 783–801, doi:10.1016/j.cell.2006.02.015 (2006).
2. Thompson, M. R., Kaminski, J. J., Kurt-Jones, E. A. & Fitzgerald, K. A. Pattern recognition receptors and the innate immune response to viral infection. Viruses 3, 920–940, doi:10.3390/v3060920 (2011).
3. Hovland, A. et al. The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis. Atherosclerosis 241, 480–494, doi:10.1016/j.atherosclerosis.2013.05.038 (2015).
4. Elsenberg, E. H. et al. Increased cytokine response after toll-like receptor stimulation in patients with stable coronary artery disease. Atherosclerosis 231, 346–351, doi:10.1016/j.atherosclerosis.2013.09.036 (2013).
5. Cole, J. E., Kassiteridi, C. & Monaco, C. Toll-like receptors in atherosclerosis: a Pandora’s box of advances and controversies. Trends Pharmacol Sci 34, 629–636, doi:10.1016/j.tips.2013.09.008 (2013).
6. Lundberg, A. M. et al. Toll-like receptor 3 and 4 signaling through the TRIF and TRAM adaptors in haematopoietic cells promotes atherosclerosis. Cardioren Res 99, 364–373, doi:10.1093/cvr/cvt033 (2013).
7. Ishibashi, M., Sayers, S., D’Armentio, J. M., Tall, A. R. & Welch, C. L. TLR3 deficiency protects against collagen degradation and medial destruction in murine atherosclerotic plaques. Atherosclerosis 229, 52–61, doi:10.1016/j.atherosclerosis.2013.03.033 (2013).
8. Ding, Y. et al. Toll-like receptor 4 deficiency decreases atherosclerosis but does not protect against inflammation in obese low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 32, 1596–1604, doi:10.1161/ATVBAHA.112.249447 (2012).
9. Hasu, M., Thabet, M., Tam, N. & Whitman, S. C. Specific loss of toll-like receptor 2 on bone marrow derived cells decreases atherosclerosis in LDL receptor null mice. Can J Physiol Pharmacol 89, 737–742, doi:10.1139/y11-071 (2011).
10. Lu, Z., Zhang, X., Li, Y., Jin, J. & Huang, Y. TLR4 antagonist reduces early-stage atherosclerosis in diabetic apolipoprotein E-deficient mice. J Endocrinol 216, 61–71, doi:10.1530/JOE-12-0338 (2013).
11. Hayashi, C. et al. Protective role for TLR4 signaling in atherosclerosis progression as revealed by infection with a common oral pathogen. J Immunol 189, 3681–3688, doi:10.4049/jimmunol.1201541 (2012).
12. Cole, J. E. et al. Unexpected protective role for Toll-like receptor 3 in the arterial wall. Proc Natl Acad Sci USA 108, 2372–2377, doi:10.1073/pnas.1018515108 (2011).
13. Koulis, C. et al. Protective role for Toll-like receptor 9 in the development of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 34, 516–525, doi:10.1161/ATVBAHA.113.302407 (2014).
14. Lund, J. M. et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 101, 5598–5603, doi:10.1073/pnas.0400937101 (2004).
15. Lau, C. M. et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 202, 1171–1177, doi:10.1084/jem.20050630 (2005).
62. Elhage, R.
63. Pejnovic, N.
87. Lin, E., Freedman, J. E. & Beaulieu, L. M. Innate immunity and toll-like receptor antagonists: a potential role in the treatment of
86. Alber, D. G., Powell, K. L., Vallance, P. & Goodwin, D. A. & Grahame-Clarke, C. Herpesvirus infection accelerates atherosclerosis in
59. Chapman, M. J.
58. Upadhyay, R. K. Emerging risk biomarkers in cardiovascular diseases and disorders. J Lipids 2015, 971453–50, doi:10.1155/2015/971453 (2015).
156. Mancuso, G.
156. Zheng, T.
59. Chapman, M. J. doi:10.1038/ni.1733 (2009).
65. Krogmann, A. O.
60. Mancuso, G.
56. Zheng, T.
58. Upadhyay, R. K. Emerging risk biomarkers in cardiovascular diseases and disorders.

Acknowledgements
The authors thank Chelsea Swallom for editorial assistance. This study is supported by grants from the Natural Science Foundation of China grants (81570274 to J.Y.Z.) and the National Institutes of Health (HL60942, HL81090, and HL123568 to G.P.S.).

Author Contributions
C.L., and M.M.S. designed and performed most of the experiment. C.F. generated mouse model. M.L. and K.I. was responsible for mouse lesion and blood characterization. J.Y.Z. was involved in experimental design. G.K.S. performed most of the lesion immunohistochemical analysis. G.P.S. designed the experiments and wrote the manuscript.
